Major First in Class Clinical data!
Genoscience is proud to announce a new cornerstone of our Ezurpimtrostat’s (GNS561) development.
The paper summarizing the phase 1b study is now approved and published in @liver cancer journal.
First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers
Authors: James J. Harding¹,2, Ahmad Awada3, Gael Roth4, Thomas Decaens4, Philippe Merle5, Nuria Kotecki3, Chantal Dreyer6, Christelle Ansaldi7, Madani Rachid7, Soraya Mezouar7, Agnes Menut7, Eloïne Nadeige Bestion7, Valérie Paradis8, Philippe Halfon7, Ghassan K. Abou-Alfa¹,2* and Eric Raymond6ʼ7*
Introduction – GNS561/Ezurpimtrostat is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase 1 (PPT1).
Methods – This phase I, open-label, dose-escalation trial (3+3 design) explored two GNS561 dosing schedules: one single oral intake three times a week (Q3W) and twice daily (BID) continuous oral administration in patients with advanced hepatocellular carcinoma, cholangiocarcinoma, and pancreatic adenocarcinoma or colorectal adenocarcinomas with liver metastasis. The primary objective was to determine GNS561 recommended phase II dose (RP2D) and schedule. Secondary objectives included evaluation of the safety/tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of GNS561.
Results – Dose escalation ranged from 50-400mg Q3W to 200-300mg BID. Among 26 evaluable patients for safety, 20 were evaluable for efficacy and no dose-limiting toxicity was observed. Adverse events (AEs) included gastrointestinal grade 1-2 events, primarily nausea and vomiting occurred in 13 (50%) and 14 (54%) patients respectively, and diarrhea in 11 (42%) patients. Seven (7) grade 3 adverse events were reported (diarrhea, decreased appetite, fatigue, ALT and AST increased). Q3W administration was associated with limited exposure and the BID schedule was preferred. At 200 mg BID GNS561, plasma and liver concentrations were comparable to active doses in animal models. Liver trough concentrations were much higher than in plasma a median time of 28 days of administration with a mean liver to plasma ratio of 9559 (Min 149-Max 25759), which is in accordance with rat preclinical data observed after repeated administration. PPT1 expression in cancer tissues in the liver was reduced upon GNS561 exposure. There was no complete or partial response. Five patients experienced tumor stable diseases (25%), including one minor response (-23%).
Conclusion – Based on a favourable safety profile, exposure, and preliminary signal of activity, oral GNS561 RP2D was set at 200mg BID. Studies to evaluate the antitumor activity of GNS561 in HCC and iCCA are to follow.
✨And thanks to James J. Harding, Ahmad Awada, Gael Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Valérie Paradis, Ghassan K. Abou-Alfa